Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ATM dec exp||stomach cancer||predicted - sensitive||PARP Inhibitor (Pan)||Olaparib + Paclitaxel||Phase II||Actionable||In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (5.29 vs 3.68 months) compared to Taxol alone, but did significantly prolong overall survival (HR = 0.35) in metastatic gastric cancer patients with decreased Atm expression (PMID: 26282658; NCT01063517).||26282658|
|ATM dec exp||breast cancer||sensitive||PARP Inhibitor (Pan)||Talazoparib||Preclinical - Cell culture||Actionable||In a preclinical study, knockdown of ATM expression sensitized breast cancer cells to treatment with Talzenna (talazoparib) in culture (PMID: 23881923).||23881923|
|ATM dec exp||stomach cancer||sensitive||PARP Inhibitor (Pan)||Veliparib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, knockdown of ATM in a gastric cancer cell line resulted in increased sensitivity to Veliparib (ABT-888) in culture and in xenograft models (PMID: 27638859).||27638859|